1.31

2.24% -0.03

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $1.31, with a volume of 4.92M. It is down -2.24% in the last 24 hours and down -22.49% over the past month. Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Previous Close:

$1.34

Open:

$1.34

24h Volume:

4.92M

Relative Volume:

0.82

Market Cap:

$452.59M

Revenue:

$22,000

Net Income/Loss:

$-173.76M

P/E Ratio:

-1.7055

EPS:

-0.7681

Net Cash Flow:

$-109.53M

1W Performance:

-10.27%

1M Performance:

-22.49%

6M Performance:

-44.73%

1Y Performance:

+3.15%

1-Day Range:

$1.29

$1.34

1-Week Range:

$1.22

$1.46

52-Week Range:

$1.04

$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

152

Twitter

@AllogeneTx

Next Earnings Date

2026-11-05

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO Allogene Therapeutics Inc	1.31	452.59M	22,000	-173.76M	-109.53M	-0.7681
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Upgrade	JP Morgan	Underweight → Neutral
Apr-10-26	Resumed	Jefferies	Buy
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Aug-08-24	Resumed	Oppenheimer	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Oct 01, 2026

Form 13D/A Allogene Therapeutics For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026

Sep 30, 2026

TPG Fully Divests Stake in Allogene Therapeutics, Reports Zero Ownership - Kalkine Media

Sep 30, 2026

At $1.55 a share, TPG funds sold Allogene Therapeutics (ALLO) stock. - Stock Titan

Sep 30, 2026

Sep 11, 2026

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Sep 11, 2026

Sep 09, 2026

Allogene CEO Zach Roberts Is Pushing to Make CAR T-Cell Therapy More Accessible: 'That's What Gets Me Out of Bed' - survivornet.com

Sep 09, 2026

Transcript : Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com

Sep 09, 2026

Allogene at Citi summit: mrD strategy and cash runway in focus - investing.com

Sep 09, 2026

Sep 06, 2026

Allogene: If MRD Holds, This Becomes A Completely Different Company - Seeking Alpha

Sep 06, 2026

Sep 03, 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer - The Globe and Mail

Sep 03, 2026

Sep 02, 2026

Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026 - marketscreener.com

Sep 02, 2026

Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026 - marketscreener.com

Sep 02, 2026

Allogene Therapeutics CFO Geoffrey Parker Announces Retirement Effective November 2026 - Kalkine Media

Sep 02, 2026

Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com Nigeria

Sep 02, 2026

Allogene Therapeutics (ALLO) CFO Retirement Highlights Challenges Amid High Price-to-Sales Valuation - GuruFocus

Sep 02, 2026

Allogene Therapeutics CFO Geoffrey Parker to Retire - marketscreener.com

Sep 02, 2026

Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com South Africa

Sep 02, 2026

Allogene CFO Geoffrey Parker to retire in November - Investing.com

Sep 02, 2026

Allogene's Geoffrey Parker to Retire as CFO, Effective Nov 6, 2026 - TradingView

Sep 02, 2026

Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com UK

Sep 02, 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - globenewswire.com

Sep 02, 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - Yahoo Finance

Sep 02, 2026

Allogene Therapeutics CFO Geoffrey Parker to Retire - Yahoo Finance

Sep 02, 2026

Aug 31, 2026

Allogene Therapeutics Announces Participation in September Investor Conference - GlobeNewswire

Aug 31, 2026

Allogene Therapeutics Announces Participation in September Investor Conference - Yahoo Finance

Aug 31, 2026

Aug 28, 2026

Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO) - Seeking Alpha

Aug 28, 2026

Aug 27, 2026